Clinical variability in approaches to polycystic ovary syndrome

J Pediatr Adolesc Gynecol. 2012 Aug;25(4):259-61. doi: 10.1016/j.jpag.2012.03.004.

Abstract

Study objective: The objective of this study was to evaluate methods of initial diagnosis and management of polycystic ovary syndrome (PCOS) among members of the North American Society for Pediatric and Adolescent Gynecology (NASPAG) to assess the degree of practice heterogeneity among specialist providers of adolescent care.

Design: Cross-sectional, anonymous, internet survey

Participants: NASPAG membership (N = 326; Respondents = 127 (39%))

Results: Percentage of respondents who incorporated specific tests at initial diagnosis was highly variable ranging from 87% (thyroid stimulating hormone) to 17% (sex hormone binding globulin). Oral contraceptives and diet modification/exercise were the most common therapies recommended by 98% and 90% of respondents respectively.

Conclusion: Considerable practice heterogeneity was present with regards to diagnostic testing for suspected PCOS. Recommendations for first-line therapy were more consistent. Future studies should clarify the clinical utility of specific diagnostic tests for adolescents, such that selection of diagnostic testing is evidence based.

MeSH terms

  • Adolescent
  • Contraceptives, Oral / therapeutic use
  • Cross-Sectional Studies
  • Data Collection
  • Exercise
  • Feeding Behavior
  • Female
  • Hormones / blood
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / diagnosis*
  • Metformin / therapeutic use
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / diagnosis*
  • Polycystic Ovary Syndrome / therapy*
  • Practice Patterns, Physicians'*
  • Referral and Consultation
  • Sex Hormone-Binding Globulin
  • Spironolactone / therapeutic use

Substances

  • Contraceptives, Oral
  • Hormones
  • Hypoglycemic Agents
  • Mineralocorticoid Receptor Antagonists
  • Sex Hormone-Binding Globulin
  • Spironolactone
  • Metformin